HSG Emerging Drug Insight

“HSG Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about (HSG) Hallux terbinafine subungual gel for Onychomycosis in the seven major markets and China. A detailed picture of the HSG for Onychomycosis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, Japan and China for the study period 2019–2032 is provided in this report along with a detailed description of the HSG for Onychomycosis.The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the HSG market forecast, analysis for Onychomycosis in the 7MM and China descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Onychomycosis.

Drug Summary

HSG is a subungual gel formulation of terbinafine hydrochloride. The company earlier investigated terbinafine micro-inserts (HTS-519) that were placed on the nail bed by a physician using a special applicator that delivers high concentrations of terbinafine hydrochloride directly and selectively to the site of the infection with minimal exposure of the body to the drug. In 2018, the company changed the course of development from micro-insert to a novel terbinafine subungual gel formulation and anticipated that it should perform better than the solid micro-inserts.

Hallux’s subungual therapy is designed to eliminate concerns associated with oral medications, including 100% patient compliance: the subungual topical is administered by a physician in a few quick and simple in-office procedures, and patients do not have to take any additional onychomycosis drugs over the 12 months it takes to regrow a clear, disease-free nail; and the risk of liver toxicity and drug interactions: with subungual topical therapy, these risks are greatly minimized as there is negligible systemic absorption with this localized approach.

Hallux’s goal is to provide high effectiveness and safety for chronic onychomycosis patients around the world. In the United States, Hallux is conducting the Phase IIa HSG-201 clinical study for the topical treatment of onychomycosis.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Hallux terbinafine subungual gel (HSG) description, mechanism of action, dosage and administration, research and development activities in Onychomycosis.
• Elaborated details on HSG regulatory milestones and other development activities have been provided in this report.
• The report also highlights the HSG research and development activity in Onychomycosis in detail across the United States, Europe, Japan and China.
• The report also covers the patents information with expiry timeline around HSG.
• The report contains forecasted sales of HSG for Onychomycosis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Onychomycosis.
• The report also features the SWOT analysis with analyst views for HSG in Onychomycosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

HSG Analytical Perspective by DelveInsight

In-depth HSG Market Assessment

This report provides a detailed market assessment of Hallux terbinafine subungual gel (HSG) in Onychomycosis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Japan and China. This segment of the report provides forecasted sales data from 2025 to 2032.

HSG Clinical Assessment

The report provides the clinical trials information of HSG in Onychomycosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Onychomycosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence HSG dominance.
• Other emerging products for Onychomycosis are expected to give tough market competition to HSG and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of HSG in Onychomycosis.
• Our in-depth analysis of the forecasted sales data from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the HSG in Onychomycosis.

Key Questions

• What is the product type, route of administration and mechanism of action of HSG?
• What is the clinical trial status of the study related to HSG in Onychomycosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the HSG development?
• What are the key designations that have been granted to HSG for Onychomycosis?
• What is the forecasted market scenario of HSG for Onychomycosis?
• What are the forecasted sales of HSG in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), Japan and China?
• What are the other emerging products available in Onychomycosis and how are they giving competition to HSG for Onychomycosis?
• Which are the late-stage emerging therapies under development for the treatment of Onychomycosis?